Braftovi Triplet Regimen Doubles Survival in BRAF V600E Metastatic Colorectal Cancer

The phase 3 BREAKWATER trial demonstrated that Braftovi (encorafenib) plus Erbitux (cetuximab) combined with chemotherapy significantly improves survival in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The combination achieved a median overall survival of 30.3 months compared to 15.1 months in the control group receiving standard-of-care chemotherapy with or without bevacizumab, representing a 51% reduction in the risk of death.

The study specifically targeted treatment-naïve patients with the BRAF V600E mutation, which affects approximately 10% of the metastatic colorectal cancer population and is historically associated with a poor prognosis. The hazard ratio for death in the primary triplet arm stood at 0.49, signaling a definitive clinical benefit.

The objective response rate significantly improved with the Braftovi-based regimen, with an odds ratio for response of 2.44 (P < 0.001). The combination demonstrated higher depth and durability of response compared with standard chemotherapy with or without bevacizumab. Patients who received the Braftovi-based regimen experienced a statistically significant and clinically meaningful improvement in progression-free survival, with the triplet achieving 12.8 months versus 7.1 months for standard chemotherapy.

In February 2026, positive topline results were reported for Cohort 3 of the study, which utilized a FOLFIRI chemotherapy backbone instead of mFOLFOX6. This additional data provides oncologists with critical flexibility, allowing for the use of different chemotherapy bases while maintaining the efficacy of the Braftovi/cetuximab targeted core. The progression-free survival improvement was assessed by an independent central review to reduce bias.

The safety profile of the combination was consistent with what is already known about each medicine, and no new safety concerns were identified. The most common grade 3 or higher side effects included neutropenia, diarrhea, peripheral neuropathy, acneiform rash (EGFR-related), and fatigue.

BRAF V600E mutations are more frequently associated with right-sided colon cancers, which typically carry worse outcomes and reduced responsiveness to conventional EGFR inhibition alone. The trial reinforces that right-sided BRAF-mutant tumors benefit from combined BRAF plus EGFR blockade.

BRAF mutations occur in approximately 8% to 12% of metastatic colorectal cancers. The V600E mutation is the most common and is associated with a poorer prognosis, including shorter survival and reduced response to traditional chemotherapy. Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related death. Approximately 20% of patients are diagnosed after the disease has already spread, and up to half of those diagnosed earlier will eventually develop metastatic disease.

The BREAKWATER trial enrolled patients who had not received prior treatment for metastatic disease. Key inclusion criteria included confirmed BRAF V600E mutation and previously untreated metastatic colorectal cancer. Key exclusion criteria included prior systemic therapy for metastatic disease and uncontrolled CNS metastases. All participants were considered appropriate candidates for combination chemotherapy.

Currently, Braftovi is approved in combination with Erbitux and mFOLFOX6 under accelerated approval for previously untreated BRAF V600E metastatic colorectal cancer, based on tumor response rates. Continued approval depends on confirming long-term clinical benefit.